-
1
-
-
0003964363
-
-
American Cancer Society. Available at
-
American Cancer Society. Cancer Facts & Figures. 2007. Available at: www.cancer.org.
-
(2007)
Cancer Facts & Figures
-
-
-
2
-
-
0032824734
-
Current management of metastatic breast cancer
-
Perez EA. Current management of metastatic breast cancer. Semin Oncol 1999;26:1-10.
-
(1999)
Semin Oncol
, vol.26
, pp. 1-10
-
-
Perez, E.A.1
-
3
-
-
14844303761
-
Capecitabine: A review
-
Walko CM, Lindley C. Capecitabine: a review. Clin Ther 2005;27:23-44.
-
(2005)
Clin Ther
, vol.27
, pp. 23-44
-
-
Walko, C.M.1
Lindley, C.2
-
4
-
-
18444417397
-
Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines
-
Talbot DC, Moiseyenko V, Van Belle S, et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002;86:1367-1372.
-
(2002)
Br J Cancer
, vol.86
, pp. 1367-1372
-
-
Talbot, D.C.1
Moiseyenko, V.2
Van Belle, S.3
-
5
-
-
1842627763
-
Oral capecitabine in anthracycline-and taxane-pretreated advanced/metastatic breast cancer
-
Wist EA, Sommer HH, Ostenstad B, et al. Oral capecitabine in anthracycline-and taxane-pretreated advanced/metastatic breast cancer. Acta Oncol 2004;43:186-189.
-
(2004)
Acta Oncol
, vol.43
, pp. 186-189
-
-
Wist, E.A.1
Sommer, H.H.2
Ostenstad, B.3
-
6
-
-
2942715243
-
Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: A multicenter phase II study
-
DOI 10.1200/JCO.2004.12.128
-
Gradishar WJ, Meza LA, Amin B, et al. Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study. J Clin Oncol 2004;22:2321-2327. (Pubitemid 41115388)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.12
, pp. 2321-2327
-
-
Gradishar, W.J.1
Meza, L.A.2
Amin, B.3
Samid, D.4
Hill, T.5
Chen, Y.-M.6
Lower, E.E.7
Marcom, P.K.8
-
7
-
-
0041508753
-
Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy
-
Reichardt P, Von Minckwitz G, Thuss-Patience PC, et al. Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003;14:1227-1233.
-
(2003)
Ann Oncol
, vol.14
, pp. 1227-1233
-
-
Reichardt, P.1
Von Minckwitz, G.2
Thuss-Patience, P.C.3
-
8
-
-
0034778024
-
Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer
-
O'Shaughnessy JA, Blum J, Moiseyenko V, et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001;12:1247-1254.
-
(2001)
Ann Oncol
, vol.12
, pp. 1247-1254
-
-
O'Shaughnessy, J.A.1
Blum, J.2
Moiseyenko, V.3
-
9
-
-
41849091764
-
A randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatment
-
ASCO Annual Meeting Proceedings, (16S), Part I of II
-
Stockler M, Sourijina T, Grimision P, et al. A randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatment. ASCO Annual Meeting Proceedings. J Clin Oncol 2007;25(June Suppl): (16S), Part I of II, 1031.
-
(2007)
J Clin Oncol
, vol.25
, Issue.JUNE SUPPL.
, pp. 1031
-
-
Stockler, M.1
Sourijina, T.2
Grimision, P.3
-
10
-
-
33644960128
-
Capecitabine monotherapy for elderly patients with metastatic breast cancer
-
Minea L, Stanculeanu DL, Cringeanu A, et al. Capecitabine monotherapy for elderly patients with metastatic breast cancer. J Clin Oncol 2004;22:76s.
-
(2004)
J Clin Oncol
, vol.22
-
-
Minea, L.1
Stanculeanu, D.L.2
Cringeanu, A.3
-
11
-
-
20244368234
-
Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women
-
Bajetta E, Procopio G, Gelio L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005;23:2155-2166.
-
(2005)
J Clin Oncol
, vol.23
, pp. 2155-2166
-
-
Bajetta, E.1
Procopio, G.2
Gelio, L.3
-
12
-
-
2942715243
-
Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: A multicenter phase II study
-
DOI 10.1200/JCO.2004.12.128
-
Gradishar WJ, Meza LA, Amin B, et al. Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study. J Clin Oncol 2004;22:2321-2327. (Pubitemid 41115388)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.12
, pp. 2321-2327
-
-
Gradishar, W.J.1
Meza, L.A.2
Amin, B.3
Samid, D.4
Hill, T.5
Chen, Y.-M.6
Lower, E.E.7
Marcom, P.K.8
-
13
-
-
0012856124
-
Phase II study of vinorelbine (Navelline) and capecitabine (C) combination (Navcap) as first line treatment of metastatic breast cancer (MBC)
-
Kattan J, Ghosn M, Farhat F, et al. Phase II study of vinorelbine (Navelline) and capecitabine (C) combination (Navcap) as first line treatment of metastatic breast cancer (MBC). Ann Oncol 2002;13(Suppl 5):56.
-
(2002)
Ann Oncol
, vol.13
, Issue.SUPPL. 5
, pp. 56
-
-
Kattan, J.1
Ghosn, M.2
Farhat, F.3
-
14
-
-
0003043509
-
Population based cost-effectiveness analysis of combination capecitabine and docstaxel (DC) versus single agent docetaxel (D) in the treatment of metastatic breast cancer (MBC) following an anthracycline regimen
-
Malfair TS, Barnett J, Chia S. Population based cost-effectiveness analysis of combination capecitabine and docstaxel (DC) versus single agent docetaxel (D) in the treatment of metastatic breast cancer (MBC) following an anthracycline regimen. Eur J Cancer 2002;38(Suppl 3):S67.
-
(2002)
Eur J Cancer
, vol.38
, Issue.SUPPL. 3
-
-
Malfair, T.S.1
Barnett, J.2
Chia, S.3
-
15
-
-
20444389366
-
Capecitabine plus docetaxel combination therapy
-
Verma S, Maraninchi D, O'Shaughnessy J, et al. Capecitabine plus docetaxel combination therapy. Cancer 2005;103:2455-2465.
-
(2005)
Cancer
, vol.103
, pp. 2455-2465
-
-
Verma, S.1
Maraninchi, D.2
O'Shaughnessy, J.3
-
16
-
-
0037683726
-
Population-based pharmacoeconomic model for adopting capecitabine/ docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer
-
Verma S, Ilersich AL. Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline- pretreated metastatic breast cancer. Oncologist 2003;8:232-240.
-
(2003)
Oncologist
, vol.8
, pp. 232-240
-
-
Verma, S.1
Ilersich, A.L.2
-
18
-
-
1442321206
-
Clinical and economic outcomes associated with metastatic breast cancer in managed care populations: Capecitabine (Xeloda) versus comparison therapies
-
abstr 1942 ASCO Annual Meeting Proceedings
-
Baran RW, Dupere W, Susan M, et al. Clinical and economic outcomes associated with metastatic breast cancer in managed care populations: capecitabine (Xeloda) versus comparison therapies. ASCO Annual Meeting Proceedings, J Clin Oncol 2002, abstr 1942.
-
(2002)
J Clin Oncol
-
-
Baran, R.W.1
Dupere, W.2
Susan, M.3
-
19
-
-
25544437658
-
Cost-effectiveness of capecitabine, continuous infusion 5-FU, gemcitabine and vinorebine in the treatment of metastatic breast cancer
-
abstr 1629 ASCO Annual Meeting Proceedings
-
Silberman G, Gupta S, Berkowitz N, et al. Cost-effectiveness of capecitabine, continuous infusion 5-FU, gemcitabine and vinorebine in the treatment of metastatic breast cancer. ASCO Annual Meeting Proceedings. J Clin Oncol 1999, abstr 1629.
-
(1999)
J Clin Oncol
-
-
Silberman, G.1
Gupta, S.2
Berkowitz, N.3
-
20
-
-
75749137109
-
Use of cancer registry data for research on patterns of breast cancer care of individuals with Medicaid Insurance
-
ASCO Annual Meeting Proceedings: (16S), Part I of II
-
Anderson RT, Camacho FT, Balkrishnan R, et al. Use of cancer registry data for research on patterns of breast cancer care of individuals with Medicaid Insurance. ASCO Annual Meeting Proceedings. J Clin Oncol 2007;25(June Suppl): (16S), Part I of II, 6021.
-
(2007)
J Clin Oncol
, vol.25
, Issue.JUNE SUPPL.
, pp. 6021
-
-
Anderson, R.T.1
Camacho, F.T.2
Balkrishnan, R.3
-
21
-
-
0030472186
-
Practical considerations on the use of the Charlson comorbidity with administrative data bases
-
D'Hoore W, Bouckaert A, Tilquin Ch. Practical considerations on the use of the Charlson comorbidity with administrative data bases. J. Clin Epidemiol 1996;49:1429-1433.
-
(1996)
J. Clin Epidemiol
, vol.49
, pp. 1429-1433
-
-
D'Hoore, W.1
Bouckaert, A.2
Tilquin, Ch.3
-
22
-
-
0033009724
-
Methods for analyzing health care utilization and costs
-
Diehr P, Yanez D, Ash A, Hornbrook, Lin DY. Methods for analyzing health care utilization and costs. Annu Rev Public Health 1999;20:125-144.
-
(1999)
Annu Rev Public Health
, vol.20
, pp. 125-144
-
-
Diehr, P.1
Yanez, D.2
Ash, A.3
Hornbrook Lin, D.Y.4
-
23
-
-
0037271111
-
Breast cancer management: Quality-of-life and cost considerations
-
DOI 10.2165/00019053-200321060-00003
-
Radice D, Redaelli A. Breast cancer management: quality-of-life and cost considerations. Pharmacoeconomics 2003;21:383-396. (Pubitemid 36461402)
-
(2003)
PharmacoEconomics
, vol.21
, Issue.6
, pp. 383-396
-
-
Radice, D.1
Redaelli, A.2
-
24
-
-
43149114465
-
Assessing the economic burden of breast cancer in a US managed care population
-
Barron JJ, Quimbo R, Nikam PT, et al. Assessing the economic burden of breast cancer in a US managed care population. Breast Cancer Res Treat 2008;109:367-377.
-
(2008)
Breast Cancer Res Treat
, vol.109
, pp. 367-377
-
-
Barron, J.J.1
Quimbo, R.2
Nikam, P.T.3
-
25
-
-
4444356391
-
The vital role of education and information in patients receiving capecitabine (Xeloda)
-
Chau I, Legge S, Fumoleau P. The vital role of education and information in patients receiving capecitabine (Xeloda). Eur J Oncol Nurs 2004;8(Suppl 1):S41-53.
-
(2004)
Eur J Oncol Nurs
, vol.8
, Issue.SUPPL. 1
-
-
Chau, I.1
Legge, S.2
Fumoleau, P.3
|